Medical imaging in clinical trials has gained momentum since the FDA began allowing imaging as part of the evidence in support of a new drug application. The FDA, in an effort to increase new drug approvals, has identified imaging as an important technology for assessing new therapeutics and accelerating drug development
in the future. There has been a big increase in demand for imaging services in the past 18 months with players ranging from Parexel to GE Medical Systems ramping up their efforts.

Medical imaging allows researchers to see the effect of a new drug more rapidly than possible when relying on traditional clinical endpoints. It plays an important role in an increasing number of clinical trials and offers sponsor companies the possibility of decreasing both time and cost in getting new pharmaceutical products
to market.

Sponsor companies increasingly depend on imaging to help them make go/no-go decisions about the products they are developing, to provide surrogate endpoints in clinical trials and to support claims about a new drug’s efficacy and safety.

Medical imaging is an increasingly important factor in the successful conduct of many clinical studies, experts claim. In addition, there has been a rise in the development of imaging core labs, which centralize quality control and assessment of images. During the past three years, these vendors have become an increasingly integral part of the clinical trial process.

PAREXEL’s Bio/Pharmaceutical R&D Statistical
Sourcebook 2008/2009

Get your copy of the leading compendium of pharma/biotech R&D trend data and market intelligence!

400+pp!  Available in Hardcopy and Electronic Access

For More information and to Order